Development of thalidomide and its IMiD derivatives

Cindy H. Chau; William Dahut; William D. Figg

doi:10.1007/978-0-387-71518-6_34

Development of thalidomide and its IMiD derivatives

Cindy H. Chau, William Dahut, William D. Figg^*

^*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Abstract

Despite its controversial past, the establishment of thalidomide as an anti-inflammatory, immunomodulatory, and antiangiogenic agent bolstered intense research into its mechanism of action and therapeutic range. The precise pharmacologic mechanism through which thalidomide exerts its activity is complex and not fully understood. The enhancement of thalidomide's immunomodulatory effects while minimizing the adverse reactions brought about a class of novel analogues termed the Immunomodulatory drugs (IMiDs). This chapter reviews and highlights some of the clinical activities and development of thalidomide and its IMiDs derivatives in the treatment of hematological cancers and various solid tumors.

Original language	English
Title of host publication	Angiogenesis
Subtitle of host publication	An Integrative Approach From Science to Medicine
Publisher	Springer US
Pages	387-394
Number of pages	8
ISBN (Print)	9780387715179
DOIs	https://doi.org/10.1007/978-0-387-71518-6_34
State	Published - 2008
Externally published	Yes

Keywords

immunomodulatory drugs
lenalidomide
multiple myeloma
thalidomide

Access to Document

10.1007/978-0-387-71518-6_34

Cite this

@inbook{95012e9e8d3646fd94549514204ab410,

title = "Development of thalidomide and its IMiD derivatives",

abstract = "Despite its controversial past, the establishment of thalidomide as an anti-inflammatory, immunomodulatory, and antiangiogenic agent bolstered intense research into its mechanism of action and therapeutic range. The precise pharmacologic mechanism through which thalidomide exerts its activity is complex and not fully understood. The enhancement of thalidomide's immunomodulatory effects while minimizing the adverse reactions brought about a class of novel analogues termed the Immunomodulatory drugs (IMiDs). This chapter reviews and highlights some of the clinical activities and development of thalidomide and its IMiDs derivatives in the treatment of hematological cancers and various solid tumors.",

keywords = "immunomodulatory drugs, lenalidomide, multiple myeloma, thalidomide",

author = "Chau, {Cindy H.} and William Dahut and Figg, {William D.}",

year = "2008",

doi = "10.1007/978-0-387-71518-6_34",

language = "English",

isbn = "9780387715179",

pages = "387--394",

booktitle = "Angiogenesis",

publisher = "Springer US",

}

TY - CHAP

T1 - Development of thalidomide and its IMiD derivatives

AU - Chau, Cindy H.

AU - Dahut, William

AU - Figg, William D.

PY - 2008

Y1 - 2008

N2 - Despite its controversial past, the establishment of thalidomide as an anti-inflammatory, immunomodulatory, and antiangiogenic agent bolstered intense research into its mechanism of action and therapeutic range. The precise pharmacologic mechanism through which thalidomide exerts its activity is complex and not fully understood. The enhancement of thalidomide's immunomodulatory effects while minimizing the adverse reactions brought about a class of novel analogues termed the Immunomodulatory drugs (IMiDs). This chapter reviews and highlights some of the clinical activities and development of thalidomide and its IMiDs derivatives in the treatment of hematological cancers and various solid tumors.

AB - Despite its controversial past, the establishment of thalidomide as an anti-inflammatory, immunomodulatory, and antiangiogenic agent bolstered intense research into its mechanism of action and therapeutic range. The precise pharmacologic mechanism through which thalidomide exerts its activity is complex and not fully understood. The enhancement of thalidomide's immunomodulatory effects while minimizing the adverse reactions brought about a class of novel analogues termed the Immunomodulatory drugs (IMiDs). This chapter reviews and highlights some of the clinical activities and development of thalidomide and its IMiDs derivatives in the treatment of hematological cancers and various solid tumors.

KW - immunomodulatory drugs

KW - lenalidomide

KW - multiple myeloma

KW - thalidomide

UR - http://www.scopus.com/inward/record.url?scp=84885736056&partnerID=8YFLogxK

U2 - 10.1007/978-0-387-71518-6_34

DO - 10.1007/978-0-387-71518-6_34

M3 - Chapter

AN - SCOPUS:84885736056

SN - 9780387715179

SP - 387

EP - 394

BT - Angiogenesis

PB - Springer US

ER -

Development of thalidomide and its IMiD derivatives

Abstract

Keywords

Access to Document

Fingerprint

Cite this